Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
暂无分享,去创建一个
Ying-Ming Pan | Z. Liao | Ri-zhen Huang | Hengshan Wang | Ying-Ming Pan | Jian-Mei Qin | Ri-Zhen Huang | Gui-Yang Yao | Zhi-Xin Liao | Heng-Shan Wang | Gui-yang Yao | Jiangke Qin | Ying‐Ming Pan
[1] E. Jacobsen,et al. Small-Molecule H-Bond Donors in Asymmetric Catalysis , 2008 .
[2] P. Richardson,et al. Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2005, Future oncology.
[3] Y. Piao,et al. Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 , 2005, Molecular Cancer Therapeutics.
[4] Carlos Alemán,et al. On the Ability of Modified Peptide Links to Form Hydrogen Bonds , 2001 .
[5] S. Hecht,et al. Synthesis of a new class of bis(thiourea)hydrazide pseudopeptides as potential inhibitors of β-sheet aggregation. , 2012, Organic letters.
[6] S Iida,et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress , 2010, Leukemia.
[7] Richard Pazdur,et al. Bortezomib for the Treatment of Mantle Cell Lymphoma , 2007, Clinical Cancer Research.
[8] M. Leippe,et al. Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. , 2009, Journal of medicinal chemistry.
[9] James Lowe,et al. Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets , 2010, Nature Reviews Drug Discovery.
[10] M. Rolfe,et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.
[11] Ri-zhen Huang,et al. Synthesis and pharmacological evaluation of dehydroabietic acid thiourea derivatives containing bisphosphonate moiety as an inducer of apoptosis. , 2016, European journal of medicinal chemistry.
[12] H. Yamaguchi,et al. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. , 2003, Cancer research.
[13] Marianne Fillet,et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.
[14] M. Groll,et al. 20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development , 2007 .
[15] James B Lorens,et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. , 2009, Blood.
[16] S. M. Gomha,et al. A facile one-pot synthesis of 6,7,8,9-tetrahydrobenzo[4,5]thieno[2,3-d]-1,2,4-triazolo[4,5-a]pyrimidin-5-ones , 2009 .
[17] L. Pfeffer,et al. Interferon Induces NF-κB-inducing Kinase/Tumor Necrosis Factor Receptor-associated Factor-dependent NF-κB Activation to Promote Cell Survival* , 2005, Journal of Biological Chemistry.
[18] T. Schirmeister,et al. Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors , 2011, ChemMedChem.
[19] R. Huber,et al. Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[20] A. Goldberg,et al. Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.
[21] Afshin Samali,et al. Mediators of endoplasmic reticulum stress‐induced apoptosis , 2006, EMBO reports.
[22] Pinaki S. Bhadury,et al. Synthesis and in vitro study of pseudo-peptide thioureas containing α-aminophosphonate moiety as potential antitumor agents. , 2010, European journal of medicinal chemistry.
[23] Xiaoyong Xu,et al. Facile and Versatile Synthesis of Alkyl and Aryl Isothiocyanates by Using Triphosgene and Cosolvent. , 2014 .
[24] E. Novellino,et al. Development of peptidomimetic boronates as proteasome inhibitors. , 2013, European journal of medicinal chemistry.
[25] G. Giaccone,et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies , 2005, Cancer.
[26] K. Anderson,et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.
[27] Cun-Yu Wang,et al. Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma Cells , 2004, Molecular and Cellular Biology.
[28] J. Friedberg,et al. BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress , 2009, Cancer biology & therapy.
[29] E. Novellino,et al. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. , 2014, European journal of medicinal chemistry.
[30] 藤田 武郎. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance , 2005 .
[31] Shiv k. Sharma,et al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. , 2010, Journal of medicinal chemistry.
[32] D. McConkey,et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. , 2005, Cancer research.
[33] Matthew Britton,et al. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. , 2009, Chemistry & biology.
[34] J. Yadav,et al. A novel trifunctional organocatalyst for the asymmetric aldol reaction: a facile enantioselective synthesis of β-hydroxyketones , 2011 .